The Journal of Urology
Volume 181, Issue 5 , Pages 2018-2026 , May 2009

Prostate Cancer Screening and Treatment in the Transplant Population: Current Status and Recommendations

Received 19 August 2008

References 

  1. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80:S254
  2. Kleinclauss F, Gigante M, Neuzillet Y, Mouzin M, Terrier N, Salomon L, et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant. 2008;23:2374
  3. Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K, et al. Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation. 2003;75:237
  4. Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transpl Int. 2006;19:908
  5. Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant. 2003;3:619
  6. Schonberger B, Giessing M, Vogler H, Budde K, Loening S. Relevance and meaning of prostate cancer in kidney transplantation. Transplant Proc. 2002;34:2225
  7. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605
  8. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997;2:14
  9. Secin FP, Carver B, Kattan MW, Eastham JA. Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate?. Transplantation. 2004;78:710
  10. Whang M, Geffner S, Khachikian Z, Kumar A, Bonomini L, Mulgaonkar S. Renal transplantation and prostate cancer: guidelines for screening and treatment. Transplant Proc. 2002;34:3196
  11. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159
  12. Bjork T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology. 1998;51:57
  13. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909
  14. Bruun L, Ekberg H, Bjork T, Lilja H, Hoglund P, Christensson A. Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol. 2004;171:1432
  15. Morton JJ, Howe SF, Lowell JA, Stratta RJ, Taylor RJ. Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol. 1995;75:498
  16. Horinaga M, Kitamura K, Saito S, Ukimura O, Nakanoma T, Okihara K, et al. Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Urol Int. 2007;78:334
  17. Harper L, McIntyre CW, MacDougall IC, Meyer P, Raine AE, Baker LR. Prostate-specific antigen levels in patients receiving long-term dialysis. Br J Urol. 1995;76:482
  18. Hayami S, Sasagawa I, Nakada T. Influence of sex hormones on prostate volume in men on hemodialysis. J Androl. 2000;21:258
  19. Khairullah QT, Pamatmat SD, Chatha M, Provenzano R, Telang D, Temple M. Early detection of prostate cancer in the ESRD population. Clin Nephrol. 2004;61:308
  20. Tarhan F, Orcun A, Kucukercan I, Camursoy N, Kuyumcuoglu U. Effect of hemodialysis on serum complexed prostate-specific antigen levels. Scand J Urol Nephrol. 2007;41:382
  21. Tzanakis I, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron. 2002;90:230
  22. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology. 1993;42:398
  23. Bruun L, Bjork T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. 2003;18:598
  24. Wolff JM, Ting O, Borchers H, Rohde D, Jakse G. Serum levels of prostate specific antigen in men on hemodialysis. Anticancer Res. 2000;20:5191
  25. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci U S A. 1990;87:3753
  26. Kolb-Bachofen V, Schlepper-Schafer J, Vogell W, Kolb H. Electron microscopic evidence for an asialoglycoprotein receptor on Kupffer cells: localization of lectin-mediated endocytosis. Cell. 1982;29:859
  27. Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate specific antigen is metabolized in the liver. J Urol. 1996;155:1332
  28. Boyle P. New insights into the epidemiology and natural history of benign prostatic hyperplasia. Prog Clin Biol Res. 1994;386:3
  29. Akdogan M, Hassoun BS, Gurakar A, El-Sahwi K, Jazzar A, Wright H, et al. Prostate-specific antigen levels among cirrhotic patients. Int J Biol Markers. 2002;17:161
  30. Jin B, McCaughan GW, Handelsman DJ. Effects of liver disease and transplantation on the human prostate. J Androl. 1999;20:559
  31. Williams PB, Eastham JA, Culkin DJ, Mata JA, Venable DD, Sartor O. Influence of hepatic function on serum levels of prostate specific antigen. J Urol. 1997;158:1867
  32. Kubota Y, Sasagawa I, Sinzawa H, Kunii T, Itoh K, Miura H, et al. Serum levels of free and total prostate-specific antigen in males with liver cirrhosis. Eur Urol. 1999;36:409
  33. Konety BR, Tewari A, Howard RJ, Barry JM, Hodge EE, Taylor R, et al. Prostate cancer in the post-transplant population (Urologic Society for Transplantation and Vascular Surgery). Urology. 1998;52:428
  34. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93
  35. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905
  36. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823
  37. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence?. Clin J Am Soc Nephrol. 2008;3(suppl.):S87
  38. Chertow GM, Paltiel AD, Owen WF, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med. 1996;156:1345
  39. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant. 2002;17:1786
  40. Penn I. Effect of immunosuppression on preexisting cancers. Transplant Proc. 1993;25:1380
  41. Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR, et al. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc. 2005;37:958
  42. Wang K, Zhang H, Li Y, Wei Q, Li H, Yang Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc. 2004;36:2068
  43. Engl T, Makarevic J, Relja B, Natsheh I, Muller I, Beecken WD, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer. 2005;5:4
  44. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology. 2005;65:91
  45. Sheil AG. Patterns of malignancies following renal transplantation. Transplant Proc. 1999;31:1263
  46. Bayne A, Barry JM, Garzotto M. Radical retropubic prostatectomy after orthotopic liver transplantation. Urology. 2005;65:175
  47. Mohammadi S, Silvaggio G, Bonnet N, Berberian G, Dorent R, Bikter M, et al. Prostate cancer after heart transplantation: unicenter case-control study. J Heart Lung Transplant. 2005;24:995
  48. Thomas AA, Nguyen MM, Gill IS. Laparoscopic transperitoneal radical prostatectomy in renal transplant recipients: a review of three cases. Urology. 2008;71:205
  49. Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008;179:1349
  50. Mouzin M, Bachaud JM, Kamar N, Gamé X, Vaessen C, Rischmann P, et al. Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation. 2004;78:1496

 Nothing to disclose.

 Editor's Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2392 and 2393.

PII: S0022-5347(09)00043-3

doi: 10.1016/j.juro.2009.01.021

The Journal of Urology
Volume 181, Issue 5 , Pages 2018-2026 , May 2009

Article Tools